Abstract
Diabetes mellitus is a major risk factor for the development of cardiovascular disease due to increased vascular inflammatory and oxidative stress favouring atherogenesis. Endothelial dysfunction has received increasing attention as a potential contributor to the pathogenesis of vascular disease in diabetes mellitus. Although the underlying cause of endothelial dysfunction is multifactorial, a key factor is impairment of the bioavailability of nitric oxide (NO). Emerging evidence suggest that upregulation of arginase is of central importance for reduced NO bioavailability due to competition for the substrate L-arginine between arginase and the endothelial form of NO synthase. Arginase is also associated with increased oxidative stress, further impairing NO bioavailability. Upregulation of arginase has been suggested to be a key factor driving endothelial dysfunction in diabetes. The present review describes the regulation of arginase in relation to diabetes and arginase as a potential therapeutic target to improve endothelial function in experimental models and the clinical setting of diabetes mellitus.
Keywords: Arginase, nitric oxide, oxidative stress, endothelium, diabetes.
Graphical Abstract
Current Vascular Pharmacology
Title:The Emerging Role of Arginase in Endothelial Dysfunction in Diabetes
Volume: 14 Issue: 2
Author(s): John Pernow and Christian Jung
Affiliation:
Keywords: Arginase, nitric oxide, oxidative stress, endothelium, diabetes.
Abstract: Diabetes mellitus is a major risk factor for the development of cardiovascular disease due to increased vascular inflammatory and oxidative stress favouring atherogenesis. Endothelial dysfunction has received increasing attention as a potential contributor to the pathogenesis of vascular disease in diabetes mellitus. Although the underlying cause of endothelial dysfunction is multifactorial, a key factor is impairment of the bioavailability of nitric oxide (NO). Emerging evidence suggest that upregulation of arginase is of central importance for reduced NO bioavailability due to competition for the substrate L-arginine between arginase and the endothelial form of NO synthase. Arginase is also associated with increased oxidative stress, further impairing NO bioavailability. Upregulation of arginase has been suggested to be a key factor driving endothelial dysfunction in diabetes. The present review describes the regulation of arginase in relation to diabetes and arginase as a potential therapeutic target to improve endothelial function in experimental models and the clinical setting of diabetes mellitus.
Export Options
About this article
Cite this article as:
Pernow John and Jung Christian, The Emerging Role of Arginase in Endothelial Dysfunction in Diabetes, Current Vascular Pharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/1570161114666151202205617
DOI https://dx.doi.org/10.2174/1570161114666151202205617 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioaccessibility of Bioactive Compounds and Prebiotic Properties of Fruit and Vegetable By-products - A Mini Review
Current Bioactive Compounds Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases
Current Pharmaceutical Design Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research Systems Biology of HBOC-Induced Vasoconstriction
Current Drug Discovery Technologies Biomarkers of Atrial Fibrillation in Metabolic Syndrome
Current Medicinal Chemistry Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets Relationships between Serotoninergic System and Skin Fibrotic
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Mesenchymal Stem Cells and C-type Natriuretic Peptide Signaling: A Proposal for a New Treatment Approach for Skeletal Dysplasias
Current Stem Cell Research & Therapy Uric Acid and Oxidative Stress
Current Pharmaceutical Design The Effects of Dietary Supplements that Overactivate the Nrf2/ARE System
Current Medicinal Chemistry Adipose Tissue Oxygenation in Obesity: A Matter of Cardiovascular Risk?
Current Pharmaceutical Design Editorial [Hot Topic: Modifying Coronary Risk Factors: C-Reactive Protein,Haemostatic Factors and Cardiovascular Risk (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design Novel Insights Into Lp(a) Physiology and Pathogenicity: More Questions Than Answers?
Cardiovascular & Hematological Disorders-Drug Targets Evaluation and Comparative Correlation of Abdominal Fat Related Parameters in Obese and Non-obese Groups Using Computed Tomography
Current Medical Imaging Applications of Arterial Spin Labelling in Mild Cognitive Impairment, Alzheimers Disease and Other Forms of Dementia
Current Medical Imaging Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials Hereditary Haemorrhagic Teleangiectasia: Diagnostic Imaging of Visceral Involvement
Current Pharmaceutical Design